Oxytocin, Stress, Craving, Opioid Use Disorder

Overview

Although stress has long been linked to substance use, craving and relapse, there are no available medications that target stress-induced substance use disorder (SUD). In particular, with the rise in opioid use, there is still a crucial need for developing effective pharmacological treatments that target and integrate the complexity of this disease. The long term goal of this project is to identify the key neuroendocrine pathways that are responsible for stress-induced craving in individuals with opioid use disorder (OUD) in order to better understand how they can be effectively treated.

Full Title of Study: “Oxytocin to Reduce Stress-induced Craving in Individuals With Opioid Use Disorder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 22, 2023

Detailed Description

The goal of this research is to evaluate whether oxytocin, a hormone with anti-stress properties, dampens the effects of stress and opioid-associated cues on opioid craving and thus may be an effective adjunctive treatment for OUD. The central hypothesis of this research is that oxytocin will reduce stress-induced opioid craving in patients with OUD treated with buprenorphine/naloxone as opioid replacement therapy (ORT). This hypothesis is based on the model of addiction (Koob, Neuron 2008) in which chronic substance use and stress lead to neurobehavioral counter-adaptations that dysregulate biobehavioral response. In this double-blind, cross-over, placebo controlled, randomized trial, individuals with OUD (N=50 who are currently receiving treatment with buprenorphine/naloxone or methadone will be randomized to intranasal oxytocin (40 international units, IU) and oxytocin-matched placebo, administered twice/day for 7 days with a minimum of two days between the opposite condition (oxytocin or placebo). On days 5 and 7, and on days 14 and 16, participants will complete two counter-balanced sessions in which they receive yohimbine (32.4 mg) or yohimbine-matched placebo.

Interventions

  • Drug: intranasal oxytocin, 40 IU, twice a day for 7 days
    • Adjunct therapy

Arms, Groups and Cohorts

  • Experimental: oxytocin
    • The oxytocin will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).
  • Placebo Comparator: matching placebo
    • The oxytocin-matched placebo will be formulated at 5mg/0.1mL (5mg/spray) and dispensed as 10-mL nasal spray, twice a day (2 sprays per nostril) for 7 days (total daily dose: 40 international units, IU).

Clinical Trial Outcome Measures

Primary Measures

  • Opioid Craving
    • Time Frame: one day
    • The primary outcome will test the effect of oxytocin, compared to placebo, on opioid craving during two laboratory stress induction, paired to a cue reactivity paradigm. The dependent measure for the primary aim is the Desire for Drug Questionnaire (DDQ) the stress induction will be done using yohimbine or matching placebo (counterbalanced) during the two laboratory sessions. At each visit the DDQ will be administered 3 times: before starting any procedure, after the yohimbine challenge, and after the cue-reactivity. This outcome will be compared between oxytocin and matching-placebo during the stress induction produced by yohimbine or matching-placebo.

Secondary Measures

  • Safety and tolerability of oxytocin and yohimbine in OUD individuals receiving buprenorphine/naloxone: side effects
    • Time Frame: one day
    • Participants will complete a laboratory session that includes a battery of medical/physiological/psychological assessments to monitor adverse events. To monitor safety and tolerability during the entire course of the study, we will examine between-group differences (oxytocin, placebo) and during yohimbine administration in reports of side effects (headache, vertigo, edema, nausea, somnolence, anxiety, abdominal pain, palpitations) at the laboratory sessions and at the follow up visit. Reporting of the study results will be of a descriptive nature and presented using summary statistics: number of subjects (n), mean (M), standard deviation (SD) or standard error of the mean (SEM), co-efficient of variation (CV), median, minimum, maximum or frequency distributions (n, %)
  • Safety and tolerability of oxytocin and yohimbine in OUD individuals receiving buprenorphine/naloxone: opiate withdrawal syndrome
    • Time Frame: one day
    • Safety measures include: opiate withdrawal syndrome by Clinical Opiate Withdrawal Scale (COWS) that will be monitored during lab sessions.
  • Safety and tolerability of oxytocin and yohimbine in OUD individuals receiving buprenorphine/naloxone: anxiety
    • Time Frame: one day
    • To monitor safety and tolerability during the entire course of the study, we will examine between-group differences (oxytocin, placebo) and during yohimbine administration in assessing anxiety using the Hamilton scale. Reporting of the study results will be of a descriptive nature and presented using summary statistics: number of subjects (n), mean (M), standard deviation (SD) or standard error of the mean (SEM), co-efficient of variation (CV), median, minimum, maximum or frequency distributions (n, %)
  • Safety and tolerability of oxytocin and yohimbine in OUD individuals receiving buprenorphine/naloxone: blood pressure (BP)
    • Time Frame: one day
    • To monitor safety and tolerability during the entire course of the study, we will examine between-group differences (oxytocin, placebo) and during yohimbine administration in reports of blood pressure. Reporting of the study results will be of a descriptive nature and presented using summary statistics: number of subjects (n), mean (M), standard deviation (SD) or standard error of the mean (SEM), co-efficient of variation (CV), median, minimum, maximum or frequency distributions (n, %)
  • Safety and tolerability of oxytocin and yohimbine in OUD individuals receiving buprenorphine/naloxone: heart rate (HR)
    • Time Frame: one day
    • To monitor safety and tolerability during the entire course of the study, we will examine between-group differences (oxytocin, placebo) and during yohimbine administration in reports of heat rate (HR). Reporting of the study results will be of a descriptive nature and presented using summary statistics: number of subjects (n), mean (M), standard deviation (SD) or standard error of the mean (SEM), co-efficient of variation (CV), median, minimum, maximum or frequency distributions (n, %)

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female (50%), 18 to 70 (inclusive) years of age; – Currently meets DSM-5 criteria for OUD; – Currently on a stable dose of buprenorphine/naloxone or methadone for at least 3 months; – In good health as confirmed by medical history, physical examination and blood work (Liver function within 5x the Upper normal limits (AST/ALT) and renal function within 2x the Lower Normal Limit (bilirubin, creatine clearance). – Willing to take medication and adhere to the study procedures;- Understand informed consent and questionnaires in English at an 8th grade level; – Clinical Opiate Withdrawal Scale (COWS) = 0 at study screening and prior laboratory sessions. Exclusion Criteria:

  • Women who are breastfeeding, test positive for pregnancy or are unwilling to use medically-approved birth control; – Suicide attempts in the last three months; – Current substance disorder other than marijuana, nicotine and caffeine as assessed by self-report and urine toxicology screen at baseline; – Current use of medications that may interact with study medications; – History of hypersensitivity to study medications; – Clinically significant electrolyte abnormalities, current rhinitis or use of vasoconstricting medications or prostaglandins.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Brown University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Carolina Haass-Koffler, Associate Professor – Brown University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.